Antibody internalization after cell surface antigen binding is critical for immunotoxin development

Shu Ru Kuo, Randall W. Alfano, Arthur E. Frankel, Jen Sing Liu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Immunotoxin potency is dependent on cell surface binding specificity as well as internalization efficiency. Current approaches for immunotoxin development are dependent on existing antibodies that were selected for high affinity and/or high production yield. However, these antibodies may demonstrate low internalization efficiency upon cell surface binding and thus are not necessarily the best candidates for immunotoxin design. Here, we have developed an assay with a novel protein, DTG3, to compare and evaluate the internalization efficiency of monoclonal antibodies in order to circumvent the possibility of low internalization. DTG3 is a fusion protein containing the N-terminus of diphtheria toxin (DT) and three copies of streptococci Protein G immunoglobulin binding domains. We show that antibody-DTG3 complexes formed in the test tube are able to bind their antigen on the target cell surface, resulting in cell internalization, DT-mediated protein synthesis inhibition, and host cell apoptosis. We tested this system with two well-studied antibodies, antihuman CD3ε, and anti-PSMA antibodies and were able to show efficiency of this assay. We further examined commercially available anti-CD123 antibodies for potential leukemia-targeting immunotoxin development. Finally, we applied this system in the early-stage screening of newly generated anti-CD123 hybridomas. Our data showed that this internalization assay system is sensitive, time efficient, and reproducible, and has provided a tool to compare monoclonal antibodies for the clinical development of effective immunotoxins for the treatment of a variety of neoplasms.

Original languageEnglish (US)
Pages (from-to)1975-1982
Number of pages8
JournalBioconjugate Chemistry
Volume20
Issue number10
DOIs
StatePublished - Oct 21 2009

Fingerprint

Immunotoxins
Surface Antigens
Antigens
Antibodies
Diphtheria Toxin
Proteins
Assays
Monoclonal antibodies
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Hybridomas
Cell death
Leukemia
Immunoglobulins
Apoptosis
Screening
Fusion reactions
Neoplasms

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Antibody internalization after cell surface antigen binding is critical for immunotoxin development. / Kuo, Shu Ru; Alfano, Randall W.; Frankel, Arthur E.; Liu, Jen Sing.

In: Bioconjugate Chemistry, Vol. 20, No. 10, 21.10.2009, p. 1975-1982.

Research output: Contribution to journalArticle

Kuo, Shu Ru ; Alfano, Randall W. ; Frankel, Arthur E. ; Liu, Jen Sing. / Antibody internalization after cell surface antigen binding is critical for immunotoxin development. In: Bioconjugate Chemistry. 2009 ; Vol. 20, No. 10. pp. 1975-1982.
@article{75b98b006ad1459a8d328748980f720a,
title = "Antibody internalization after cell surface antigen binding is critical for immunotoxin development",
abstract = "Immunotoxin potency is dependent on cell surface binding specificity as well as internalization efficiency. Current approaches for immunotoxin development are dependent on existing antibodies that were selected for high affinity and/or high production yield. However, these antibodies may demonstrate low internalization efficiency upon cell surface binding and thus are not necessarily the best candidates for immunotoxin design. Here, we have developed an assay with a novel protein, DTG3, to compare and evaluate the internalization efficiency of monoclonal antibodies in order to circumvent the possibility of low internalization. DTG3 is a fusion protein containing the N-terminus of diphtheria toxin (DT) and three copies of streptococci Protein G immunoglobulin binding domains. We show that antibody-DTG3 complexes formed in the test tube are able to bind their antigen on the target cell surface, resulting in cell internalization, DT-mediated protein synthesis inhibition, and host cell apoptosis. We tested this system with two well-studied antibodies, antihuman CD3ε, and anti-PSMA antibodies and were able to show efficiency of this assay. We further examined commercially available anti-CD123 antibodies for potential leukemia-targeting immunotoxin development. Finally, we applied this system in the early-stage screening of newly generated anti-CD123 hybridomas. Our data showed that this internalization assay system is sensitive, time efficient, and reproducible, and has provided a tool to compare monoclonal antibodies for the clinical development of effective immunotoxins for the treatment of a variety of neoplasms.",
author = "Kuo, {Shu Ru} and Alfano, {Randall W.} and Frankel, {Arthur E.} and Liu, {Jen Sing}",
year = "2009",
month = "10",
day = "21",
doi = "10.1021/bc900333j",
language = "English (US)",
volume = "20",
pages = "1975--1982",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Antibody internalization after cell surface antigen binding is critical for immunotoxin development

AU - Kuo, Shu Ru

AU - Alfano, Randall W.

AU - Frankel, Arthur E.

AU - Liu, Jen Sing

PY - 2009/10/21

Y1 - 2009/10/21

N2 - Immunotoxin potency is dependent on cell surface binding specificity as well as internalization efficiency. Current approaches for immunotoxin development are dependent on existing antibodies that were selected for high affinity and/or high production yield. However, these antibodies may demonstrate low internalization efficiency upon cell surface binding and thus are not necessarily the best candidates for immunotoxin design. Here, we have developed an assay with a novel protein, DTG3, to compare and evaluate the internalization efficiency of monoclonal antibodies in order to circumvent the possibility of low internalization. DTG3 is a fusion protein containing the N-terminus of diphtheria toxin (DT) and three copies of streptococci Protein G immunoglobulin binding domains. We show that antibody-DTG3 complexes formed in the test tube are able to bind their antigen on the target cell surface, resulting in cell internalization, DT-mediated protein synthesis inhibition, and host cell apoptosis. We tested this system with two well-studied antibodies, antihuman CD3ε, and anti-PSMA antibodies and were able to show efficiency of this assay. We further examined commercially available anti-CD123 antibodies for potential leukemia-targeting immunotoxin development. Finally, we applied this system in the early-stage screening of newly generated anti-CD123 hybridomas. Our data showed that this internalization assay system is sensitive, time efficient, and reproducible, and has provided a tool to compare monoclonal antibodies for the clinical development of effective immunotoxins for the treatment of a variety of neoplasms.

AB - Immunotoxin potency is dependent on cell surface binding specificity as well as internalization efficiency. Current approaches for immunotoxin development are dependent on existing antibodies that were selected for high affinity and/or high production yield. However, these antibodies may demonstrate low internalization efficiency upon cell surface binding and thus are not necessarily the best candidates for immunotoxin design. Here, we have developed an assay with a novel protein, DTG3, to compare and evaluate the internalization efficiency of monoclonal antibodies in order to circumvent the possibility of low internalization. DTG3 is a fusion protein containing the N-terminus of diphtheria toxin (DT) and three copies of streptococci Protein G immunoglobulin binding domains. We show that antibody-DTG3 complexes formed in the test tube are able to bind their antigen on the target cell surface, resulting in cell internalization, DT-mediated protein synthesis inhibition, and host cell apoptosis. We tested this system with two well-studied antibodies, antihuman CD3ε, and anti-PSMA antibodies and were able to show efficiency of this assay. We further examined commercially available anti-CD123 antibodies for potential leukemia-targeting immunotoxin development. Finally, we applied this system in the early-stage screening of newly generated anti-CD123 hybridomas. Our data showed that this internalization assay system is sensitive, time efficient, and reproducible, and has provided a tool to compare monoclonal antibodies for the clinical development of effective immunotoxins for the treatment of a variety of neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=70350323728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350323728&partnerID=8YFLogxK

U2 - 10.1021/bc900333j

DO - 10.1021/bc900333j

M3 - Article

C2 - 19785403

AN - SCOPUS:70350323728

VL - 20

SP - 1975

EP - 1982

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 10

ER -